Short answer
HAEMONETICS CORP (HAE) filed its Q4 2025 10-Q quarterly report on Feb 5, 2026 for the quarter ended Dec 27, 2025. Quarterly revenue was $339M (down 2.7% year over year) with net income of $45M.
Q4 2025 key financials · XBRL
- Revenue
- $339M
- −2.7% YoY · +3.6% QoQ
- Net income
- $45M
- +19.3% YoY · +15.7% QoQ
- Operating margin
- 19.9%
- Gross margin
- 59.7%
- EPS (diluted)
- $0.95
- +28.4% YoY · +17.3% QoQ
Source: XBRL data from the HAEMONETICS CORP (HAE) Q4 2025 10-Q on SEC EDGAR. USD.
HAEMONETICS CORP Q4 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly added geopolitical risk: heightened tensions in China, Taiwan, Russia, Ukraine, and the Middle East affecting operations
- Most materially updated operational risk: supply chain disruptions due to climate change, labor strikes, terrorism, and cyber incidents
- Regulatory risk: increased complexity from EU Medical Device Regulation and In Vitro Diagnostic Regulation compliance requirements
- Market risk: pricing pressures from healthcare cost containment and consolidation among healthcare providers
- Financial risk: ability to meet debt obligations and manage convertible senior notes with capped call transactions
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other HAEMONETICS CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.